Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582775 · ClinicalTrials.gov registry record · Phase 2
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02582775: Completed Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT02582775 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02582775, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a single-institution, phase II study to determine the event-free survival at 1 year post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related donor (HLA identical, mismatched or haploidentical) or matched unrelated donor for the biochemical correction of severe epidermolysis bullosa (EB).
Primary Outcome
An event defined as death or a 50% increase in a patient's IScoreEB from baseline
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Thymoglobulin
- RADIATION Total Body Irradiation
- PROCEDURE Bone marrow infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-03 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 2 |
What the finished NCT02582775 record still lists
NCT02582775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02582775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02582775 about?
NCT02582775 is a clinical study titled "MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs". This is a single-institution, phase II study to determine the event-free survival at 1 year post allogeneic transplant and serial mesenchymal stem cell (MSC) infusions from a related donor (HLA identical, mismatched or haploidentical) or matched unrelated donor for the biochemical correction of seve...
What is the current status of trial NCT02582775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2016-03. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT02582775?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Thymoglobulin (DRUG), Total Body Irradiation (RADIATION), Bone marrow infusion (PROCEDURE).
Who is sponsoring clinical trial NCT02582775?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02582775's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia